Erratum: Impact of Molecular Genetics on Congenital Adrenal Hyperplasia Management. Sex Dev 2010;4:233-248 (DOI: 10.1159/000315959);Impact of molecular genetics on congenital adrenal hyperplasia management

Sexual Development

Volumn 4, Issue 4-5, 2010, Pages 233-248

  Balsamo, A ^a   Baldazzi, L ^a   Menabo S ^a   Cicognani, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

21 hydroxylase deficiency; CYP21A2; Genetics; Management; Modifier gene; Neonatal screening; POR deficiency; Prenatal diagnosis

Indexed keywords

CYP21A2 PROTEIN, HUMAN; STEROID 21 MONOOXYGENASE;

CONGENITAL ADRENAL HYPERPLASIA; GENETIC COUNSELING; GENETICS; HUMAN; MOLECULAR BIOLOGY; MUTATION; PHENOTYPE; REVIEW;

ADRENAL HYPERPLASIA, CONGENITAL; GENETIC COUNSELING; HUMANS; MOLECULAR BIOLOGY; MUTATION; PHENOTYPE; STEROID 21-HYDROXYLASE;

EID: 84882299078     PISSN: 16615425     EISSN: 16615433     Source Type: Journal    
DOI: 10.1159/000342192     Document Type: Erratum

References (80)

1. Alesci S, Ramsey WJ, Bornstein SR, Chrousos GP, Hornsby PJ, et al: Adenoviral vectors can impair adrenocortical steroidogenesis: clinical implications for natural infections and gene therapy. Proc Natl Acad Sci USA 99: 7484-7489 (2002).
2. Avent ND, Chitty LS: Non invasive diagnosis of fetal sex; utilisation of free fetal DNA in maternal plasma and ultrasound. Prenat Diagn 26: 598-603 (2006).
3. Bachega TA, Billerbeck AE, Marcondes JA, Madureira G, Arnhold IJ, et al: Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 52: 601-607 (2000).
4. Balsamo A, Cacciari E, Piazzi S, Cassio A, Bozza D, et al: Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics 98: 362-367 (1996).
5. Balsamo A, Cacciari E, Baldazzi L, Tartaglia L, Cassio A, et al: CYP21 analysis and phenotype/ genotype relationship in the screened population of the Italian Emilia-Romagna region. Clin Endocrinol (Oxf) 53: 117-125 (2000).
6. Balsamo A, Cicognani A, Baldazzi L, Barbaro M, Baronio F, et al: CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab 88: 5680-5688 (2003).
7. Barbaro M, Lajic S, Baldazzi L, Balsamo A, Pirazzoli P, et al: Functional analysis of two recurrent amino acid substitutions in the CYP21 gene from Italian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 89: 2402-2407 (2004).
8. Barbaro M, Baldazzi L, Balsamo A, Lajic S, Robins T, et al: Functional studies of two new and two rare mutations in the 21-hydroxylase gene. J Mol Med 84: 521-528 (2006).
9. Bartha JL, Finning K, Soothill PW: Fetal sex determination from maternal blood at 6 weeks of gestation when at risk for 21-hydroxylase deficiency. Obstet Gynecol 101: 1135-1136 (2003).
10. Baumgartner-Parzer SM, Fischer G, Vierhapper H: Predisposition for de novo gene aberrations in the offspring of mothers with a duplicated CYP21A2 gene. J Clin Endocrinol Metab 92: 1164-1167 (2007).
11. Bidet M, Bellanné-Chantelot C, Galand-Portier MB, Tardy V, Billaud L, et al: Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 94: 1570-1578 (2009).
12. Blanchong CA, Zhou B, Rupert KL, Chung EK, Jones KN, et al: Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in Caucasians.s The load of RCCX genetic diversity on major histocompatibility complex-associated disease. J Exp Med 191: 2183-2196 (2000).
13. Boon EM, Schlecht HB, Martin P, Daniels G, Vossen RH, et al: Y chromosome detection by real time PCR and pyrophosphorolysisactivated polymerisation using free fetal DNA isolated from maternal plasma. Prenat Diagn 27: 932-937 (2007).
14. Charmandari E, Eisenhofer G, Mehlinger SL, Carlson A, Wesley R, et al: Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. J Clin Endocrinol Metab 87: 3031-3037 (2002).
15. Chiu RW, Lau TK, Cheung PT, Gong ZQ, Leung TN, et al: Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: a feasibility study. Clin Chem 48: 778-780 (2002).
16. Cirigliano V, Voglino G, Ordoñez E, Marongiu A, Paz Cañadas M, et al: Rapid prenatal diagnosis of common chromosome aneuploidies by QF-PCR, results of 9 years of clinical experience. Prenat Diagn 29: 40-49 (2009).
17. Cooper DY, Levin S, Narasimhulu S, Rosenthal O: Photochemical action spectrum of the terminal oxydase of mixed function oxydase systems. Science 147: 400-402 (1965).
18. David M, Forest MG: Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr 105: 799-803 (1984).
19. Day DJ, Speiser PW, Shultz E, Bettendorf M, Fitness J, et al: Identification of non-amplifying CYP21 genes when using PCR based diagnosis of 21-hydoxylase deficiency in congenital adrenal hyperplasia (CAH) affected pedigrees. Hum Mol Genet 5: 2039-2048 (1996).
20. De Crecchio L: Sopra un caso di apparenze virili in una donna. Morgagni 7: 154-188 (1865).
21. Demirci C, Witchel SF: Congenital adrenal hyperplasia. Dermatol Ther 21: 340-353 (2008).
22. Dubey S, Idicula-Thomas S, Anwaruddin M, Saravanan C, Varma RR, et al: A novel 9-bp insertion detected in steroid 21-hydroxylase gene (CYP21A2) : prediction of its structural and functional implications by computational methods. J Biomed Sci 16: 3 (2009).
23. Ezquieta B, Cueva E, Varela J, Oliver A, Fernández J, et al: Non-classical 21-hydroxylase deficiency in children: association of adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone with the risk of compound heterozygosity with severe mutations. Acta Paediatr 91: 892-898 (2002).
24. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, et al: Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36: 228-230 (2004).
25. Forest MG, Tardy V, Nicolino M, David M, Morel Y: 21-hydroxylase deficiency: an exemplary model of the contribution of molecular biology in the understanding and management of the disease. Ann Endocrinol 66: 225-232 (2005).
26. Gomes LG, Huang N, Agrawal V, Mendonça BB, Bachega TA, et al: The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. J Clin Endocrinol Metab 93: 2913-2916 (2008).
27. Gomes LG, Huang N, Agrawal V, Mendonça BB, Bachega TA, et al: Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency. J Clin Endocrinol Metab 94: 89-95 (2009).
28. Gourmelen M, Gueux B, Pham Huu Trung MT, Fiet J, Raux-Demay MC, et al: Detection of heterozygous carriers for 21-hydroxylase deficiency by plasma 21-deoxycortisol measurement. Acta Endocrinol (Copenh) 116: 507-512 (1987).
29. Hughes IA: Disorders of sex development: a new definition and classification. Best Pract Res Clin Endocrinol Metab 22: 119-134 (2008).
30. Hurwitz A, Brautbar C, Milwidsky A, Vecsei P, Milewicz A, et al: Combined 21- and 11 betahydroxylase deficiency in familial congenital adrenal hyperplasia. J Clin Endocrinol Metab 60: 631-638 (1985).
31. Huynh T, McGown I, Cowley D, Nyunt O, Leong GM, et al: The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency. Clin Biochem Rev 30: 75-86 (2009).
32. Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, et al: Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatographytandem mass spectrometry. J Clin Endocrinol Metab 92: 2581-2589 (2007).
33. Kösel S, Burggraf S, Fingerhut R, Dörr HG, Roscher AA, et al: Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem 51: 298-304 (2005).
34. Koppens PF, Hoogenboezem T, Degenhart HJ: Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: characteristics of three unusual haplotypes. Hum Genet 111: 405-410 (2002).
35. Krone N, Arlt W: Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 23: 181-192 (2009).
36. Krone N, Braun A, Rosher AA, Knorr D, Schwarz HP: Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 85: 1059-1065 (2000).
37. Krone N, Braun A, Weinert S, Peter M, Roscher AA, et al: Multiplex minisequencing of the 21-hydroxylase gene as a rapid strategy to confirm congenital adrenal hyperplasia. Clin Chem 48: 818-825 (2002).
38. Lajic S, Levo A, Nikoshkov A, Lundberg Y, Partanen J, Wedell A: A cluster of missense mutations at Arg356 of human steroid 21-hydroxylase may impair redox partner interaction . Hum Genet 99: 704-709 (1997).
39. L'Allemand D, Tardy V, Grüters A, Schnabel D, Krude H, et al: How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 85: 4562-4567 (2000).
40. Lapaire O, Lu XY, Johnson KL, Jarrah Z, Stroh H, et al: Array-CGH analysis of cell-free fetal DNA in 10 mL of amniotic fluid supernatant. Prenat Diagn 27: 616-621 (2007).
41. Lee HH: The chimeric CYP21P/CYP21 gene and 21-hydroxylase deficiency. J Hum Genet 49: 65-72 (2004).
42. Lee HH, Lee YJ, Chao MC: Comparing the Southern blot method and polymerase chain reaction product analysis for chimeric RCCX detection in CYP21A2 deficiency. Anal Biochem 399: 293-298 (2010).
43. Levine LS, Zachmann M, New MI, Prader A, Pollack MS, et al: Genetic mapping of the 21-hydroxylase-deficiency gene within the HLA linkage group. N Engl J Med 299: 911-915 (1978).
44. Li Y, Zimmerman B, Rusterholtz C, Kang A, Holzgreve W, et al: Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. Clin Chem 50: 1002-1011 (2004).
45. Maron JL, Bianchi DW: Prenatal diagnosis using cell-free nucleic acids in maternal body fluids: a decade of progress. Am J Med Genet C Semin Med Genet 145C:5-17 (2007).
46. Martin Ritzén E, Lajic S, Wedell A: How can molecular biology contribute to the management of congenital adrenal hyperplasia? Horm Res 53 Suppl 1: 34-37 (2000).
47. Merke DP, Chrousos GP, Eisenhofer G, Weise M, Keil MF, et al: Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 343: 1362-1368 (2000).
48. Miller WL: Molecular biology of steroid hormone synthesis. Endocr rev 9: 295-318 (1988).
49. Miller WL: P450 oxidoreductase deficiency. A new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab 15: 311-315 (2004).
50. Miller WL, Huang N, Agrawal V, Giacomini KM: Genetic variation in human P450 oxidoreductase. Mol Cell Endocrinol 300: 180-184 (2009).
51. Minutti CZ, Lacey JM, Magera MJ, Hahn SH, McCann M, et al: Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 89: 3687-3693 (2004).
52. New MI: Inborn errors of adrenal steroidogenesis. Mol Cell Endocrinol 211: 75-83 (2003).
53. Nordenstrom A, Marcus C, Axelson M, Wedell A, Ritzen EM: Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective hydroxysteroid dehydrogenase reductase activity. 84: 1210-1213 (1999).
54. Olney RC, Mougey EB, Wang J, Shulman DI, Sylvester J: Using real-time, quantitative PCR for rapid genotyping of the steroid 21-hydroxylase gene in a north Florida population. J Clin Endocrinol Metab 87: 735-741 (2002).
55. Pang S, Clark A: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 2: 105-139 (1993).
56. Parajes S, Quinteiro, Dominguez F, Loidi L: High frequency of copy number variations and sequence variants at CYP21A2 locus: implication for the genetic diagnosis of 21-hydroxylase deficiency. PloS One 3:e2138 (2008).
57. Penny R, Vecsei P: Congenital adrenal hyperplasia due to combined 21- and 11-hydroxylase deficiency. J Endocrinol Invest 12: 723-728 (1989).
58. Riepe FG, Sippel WG: Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Rev Endocr Metab Disord 8: 349-363 (2007).
59. Riepe FG, Hiort O, Grötzinger J, Sippell WG, Krone N, et al: Functional and structural consequences of a novel point mutation in the CYP21A2 gene causing congenital adrenal hyperplasia: potential relevance of helix C for P450 oxidoreductase-21-hydroxylase interaction. J Clin Endocrinol Metab 93: 2891-2895 (2008).
60. Robins T, Carlsson J, Sunnerhagen M, Wedell A, Persson B: Molecular model of human CYP21 based on mammalian CYP2C5: structural features correlate with clinical severity of mutations causing congenital adrenal hyperplasia. Mol Endocrinol 20: 2946-2964 (2006).
61. Rocha RO, Billerbeck AE, Pinto EM, Melo KF, Lin CJ, et al: The degree of external genitalia virilization in girls with 21-hydroxylase deficiency appears to be influenced by the CAG repeats in the androgen receptor gene. Clin Endocrinol 68: 226-232 (2008).
62. Scott RR, Gomes LG, Huang N, Van Vliet G, Miller WL: Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J Clin Endocrinol Metab 92: 2318-2322 (2007).
63. Sikora A, Zimmermann BG, Rusterholz C, Birri D, Kolla V, et al: Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin Chem 56: 136-138 (2010).
64. Silveira EL, Elnecave RH, dos Santos EP, Moura V, Pinto EM, et al: Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia. Clin Genet 76: 503-510 (2009).
65. Sinnott PJ, Costigan C, Dyer PA, Harris R, Strachan T: Extended MHC haplotypes and CYP21/C4 gene organisation in Irish 21-hydroxylase deficiency families. Hum Genet 87: 361-366 (1991).
66. Speiser PW, Dupont B, Rubinstain P et al: High frequency of non classical steroid 21-hydroxylase deficiency. Am J Hum Genet 37: 650-667 (1985).
67. Speiser PW, Agdere L, Ueshiba H, White PC, New MI: Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase. N Engl J Med 324: 145-149 (1991).
68. Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, et al: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 90: 584-595 (1992).
69. Stanghellini I, Bertorelli R, Capone L, Mazza V, Neri C, et al: Quantitation of fetal DNA in maternal serum during the first trimester of pregnancy by the use of a DAZ repetitive probe. Mol Hum Reprod 12: 587-591 (2006).
70. Tajima T, Okada T, Ma XM, Ramsey W, Bornstein S, et al: Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochromeP450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice. Gene Ther 6: 1898-1903 (1999).
71. Tang DL, Li Y, Zhou X, Li X, Zheng F: Multiplex fluorescent PCR for noninvasive prenatal detection of fetal-derived paternally inherited diseases using circulatory fetal DNA in maternal plasma. Eur J Obstet Gynecol Reprod Biol 144: 35-39 (2009).
72. Tonetto-Fernandes V, Lemos-Marini SH, Kuperman H, Ribeiro-Neto LM, Verreschi IT, et al: Serum 21-deoxycortisol, 17-hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11beta-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency. J Clin Endocrinol Metab 91: 2179-2184 (2006).
73. Wedell A, Thilén A, Ritzén EM, Stengler B, Luthman H: Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 78: 1145-1152 (1994a).
74. Wedell A, Stengler B, Luthman H: Characterization of mutations on the rare duplicated C4/ CYP21 haplotype in steroid 21-hydroxylase deficiency. Hum Genet 94: 50-54 (1994b).
75. Welzel M, Schwarz P, Hedderich J, Dorr HG, Binder G, et al: No correlation between androgen receptor CAG and GGN repeat length and the degree of genital virilization in females with 21-hydroxylase deficiency. J Clin Endocrinol Metab, Epub ahead of print, doi:10.1210/jc.2009-133822 (2010).
76. White PC: Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 5: 490-498 (2009).
77. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21: 245-291 (2000).
78. Wilkins L, Lewis RA, Klein R, Rosemberg E: The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp 86: 249-252 (1950).
79. Yamazaki H, Shimada T: Progesterone and testosterone hydroxylation by cytochromes P4502C19, 2C9 and 3A4. Arch Biochem Biophys 346: 161-169 (1997).
80. Yang Z, Mendoza AR, Welch TR, Zipf WB, Yu CY: Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletions and disease associations. J Biol Chem 274: 12147-12156 (1999).